<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Publishing DTD v1.3 20210610//EN" "JATS-journalpublishing1-3.dtd">
<article article-type="research-article" dtd-version="1.3" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xml:lang="ru"><front><journal-meta><journal-id journal-id-type="publisher-id">vmireaviz</journal-id><journal-title-group><journal-title xml:lang="ru">Вестник медицинского института «РЕАВИЗ». Реабилитация, Врач и Здоровье</journal-title><trans-title-group xml:lang="en"><trans-title>Bulletin of the Medical Institute "REAVIZ" (REHABILITATION, DOCTOR AND HEALTH)</trans-title></trans-title-group></journal-title-group><issn pub-type="ppub">2226-762X</issn><issn pub-type="epub">2782-1579</issn><publisher><publisher-name>РЕАВИЗ</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="doi">10.20340/vmi-rvz.2025.3.CLIN.6</article-id><article-id custom-type="elpub" pub-id-type="custom">vmireaviz-1275</article-id><article-categories><subj-group subj-group-type="heading"><subject>Research Article</subject></subj-group><subj-group subj-group-type="section-heading" xml:lang="ru"><subject>Клиническая медицина</subject></subj-group><subj-group subj-group-type="section-heading" xml:lang="en"><subject>Clinical medicine</subject></subj-group></article-categories><title-group><article-title>Терапия хронической сердечной недостаточности у больных гиперчувствительным пневмонитом и ишемической болезнью сердца</article-title><trans-title-group xml:lang="en"><trans-title>Therapy of chronic heart failure in patients with hypersensitivity pneumonitis and coronary heart disease</trans-title></trans-title-group></title-group><contrib-group><contrib contrib-type="author" corresp="yes"><contrib-id contrib-id-type="orcid">https://orcid.org/0009-0006-5473-7886</contrib-id><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Медведев</surname><given-names>А. В.</given-names></name><name name-style="western" xml:lang="en"><surname>Medvedev</surname><given-names>A. V.</given-names></name></name-alternatives><bio xml:lang="ru"><p>Медведев Александр Владимирович - Канд. мед. наук, старший научный сотрудник отдела дифференциальной диагностики туберкулёза лёгких и экстракорпоральных методов лечения Вклад автора: сбор клинического материала, анализ и интерпретация результатов обследования, статистическая обработка данных, написание текста рукописи, обзор публикаций по теме статьи.</p><p>ул. Яузская аллея д. 2, г. Москва, 107564</p></bio><bio xml:lang="en"><p>Aleksandr V. Medvedev - Cand. Sci. (Med.), Senior Researcher, Department of Differential Diagnostics of Pulmonary Tuberculosis and Extracorporeal Treatment Methods Author's contribution: collection of clinical material, analysis and interpretation of examination results, statistical processing of data, writing the manuscript, review of publications on the topic of the article.</p><p>2, Yauzskaya alley str., Moscow, 107564</p></bio><email xlink:type="simple">alexmedved_1@mail.ru</email><xref ref-type="aff" rid="aff-1"/></contrib><contrib contrib-type="author" corresp="yes"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0002-6917-3220</contrib-id><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Аличубанова</surname><given-names>Г. Э.</given-names></name><name name-style="western" xml:lang="en"><surname>Alichubanova</surname><given-names>G. E.</given-names></name></name-alternatives><bio xml:lang="ru"><p>Аличубанова Гюлжаган Эльдаровна - Аспирант отдела дифференциальной диагностики туберкулёза лёгких и экстракорпоральных методов лечения Вклад автора: отбор, обследование и лечение пациентов, статистический анализ полученных данных.</p><p>ул. Яузская аллея д. 2, г. Москва, 107564</p></bio><bio xml:lang="en"><p>Gyulzhagan E. Alichubanova - Postgraduate student, Department of Differential Diagnostics of Pulmonary Tuberculosis and Extracorporeal Treatment Methods Author's contribution: selection, examination and treatment of patients, statistical analysis of the obtained data.</p><p>2, Yauzskaya alley str., Moscow, 107564</p></bio><email xlink:type="simple">alichubanova@bk.ru</email><xref ref-type="aff" rid="aff-1"/></contrib><contrib contrib-type="author" corresp="yes"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0002-4776-189X</contrib-id><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Демьяненко</surname><given-names>Н. Г.</given-names></name><name name-style="western" xml:lang="en"><surname>Dem'yanenko</surname><given-names>N. G.</given-names></name></name-alternatives><bio xml:lang="ru"><p>Демьяненко Наталья Геннадьевна - Канд. мед. наук, научный сотрудник, заведующая вторым терапевтическим отделением отдела дифференциальной диагностики туберкулёза лёгких и экстракорпоральных методов лечения Вклад автора: отбор, обследование и лечение пациентов, утверждение рукописи для публикации.</p><p>ул. Яузская аллея д. 2, г. Москва, 107564</p></bio><bio xml:lang="en"><p>Natal'ya G. Dem'yanenko - Cand. Sci. (Med.), research fellow, head of the second therapeutic department of the department of differential diagnostics of pulmonary tuberculosis and extracorporeal treatment methods Author's contribution: selection, examination and treatment of patients, approval of the manuscript for publication.</p><p>2, Yauzskaya alley str., Moscow, 107564</p></bio><email xlink:type="simple">nat.demyanencko1015@yandex.ru</email><xref ref-type="aff" rid="aff-1"/></contrib><contrib contrib-type="author" corresp="yes"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0001-5303-443X</contrib-id><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Касимцева</surname><given-names>С. А.</given-names></name><name name-style="western" xml:lang="en"><surname>Kasimtseva</surname><given-names>S. A.</given-names></name></name-alternatives><bio xml:lang="ru"><p>Касимцева Светлана Александровна - Канд. мед. наук, научный сотрудник отдела по подготовке кадров высшей квалификации последипломного образования и телемедицины Вклад автора: сбор клинического материала, анализ и интерпретация результатов обследования, статистическая обработка данных.</p><p>ул. Яузская аллея д. 2, г. Москва, 107564</p></bio><bio xml:lang="en"><p>Svetlana A. Kasimtseva - Cand. Sci. (Med.), research fellow of the department for training highly qualified personnel for postgraduate education and telemedicine Author's contribution: collection of clinical material, analysis and interpretation of examination results, statistical data processing.</p><p>2, Yauzskaya alley str., Moscow, 107564</p></bio><email xlink:type="simple">education_cniit@mail.ru</email><xref ref-type="aff" rid="aff-1"/></contrib><contrib contrib-type="author" corresp="yes"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0001-8728-2634</contrib-id><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Ковалевская</surname><given-names>М. Н.</given-names></name><name name-style="western" xml:lang="en"><surname>Kovalevskaya</surname><given-names>M. N.</given-names></name></name-alternatives><bio xml:lang="ru"><p>Ковалевская Марина Николаевна - Канд. мед. наук, главный врач Вклад автора: разработка дизайна исследования, проверка критически важного содержания, утверждение рукописи для публикации.</p><p>ул. Яузская аллея д. 2, г. Москва, 107564</p></bio><bio xml:lang="en"><p>Marina N. Kovalevskaya - Cand. Sci. (Med.), Chief Physician Author contributions: study design development, review of critical content, approval of the manuscript for publication.</p><p>2, Yauzskaya alley str., Moscow, 107564</p></bio><email xlink:type="simple">m.kovalevskaya@ctri.ru</email><xref ref-type="aff" rid="aff-1"/></contrib><contrib contrib-type="author" corresp="yes"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0001-9498-1142</contrib-id><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Тарасов</surname><given-names>Р. В.</given-names></name><name name-style="western" xml:lang="en"><surname>Tarasov</surname><given-names>R. V.</given-names></name></name-alternatives><bio xml:lang="ru"><p>Тарасов Руслан Вячеславович - Канд. мед. наук, научный сотрудник, торакальный хирург первого хирургического отделения; доцент кафедры хирургических болезней; ассистент кафедры торакальной хирургии имени академика Л.К. Богуша Вклад автора: обзор публикаций по теме статьи, анализ и интерпретация результатов обследования, написание текста рукописи.</p><p>ул. Яузская аллея д. 2, г. Москва, 107564;Краснобогатырская ул., д. 2, стр. 2, Москва, 107564;ул. Баррикадная, д. 2/1, стр. 1, г. Москва, 125993</p></bio><bio xml:lang="en"><p>Ruslan V. Tarasov - Cand. Sci. (Med.), research fellow, thoracic surgeon of the first surgical department; associate professor of the department of surgical diseases; assistant of the department of thoracic surgery named after Academician L.K. Bogush Author's contribution: review of publications on the topic of the article, analysis and interpretation of survey results, writing of the manuscript text.</p><p>2, Yauzskaya alley str., Moscow, 107564;2, Krasnobogatyrskaya str., building 2, Moscow, 107564;2/1, Barrikadnaya str., building 1, Moscow, 125993</p></bio><email xlink:type="simple">etavnai@yandex.ru</email><xref ref-type="aff" rid="aff-2"/></contrib></contrib-group><aff-alternatives id="aff-1"><aff xml:lang="ru">Центральный научно-исследовательский институт туберкулёза<country>Россия</country></aff><aff xml:lang="en">Central Research Institute of Tuberculosis<country>Russian Federation</country></aff></aff-alternatives><aff-alternatives id="aff-2"><aff xml:lang="ru">Центральный научно-исследовательский институт туберкулёза;&#13;
Московский медицинский университет «Реавиз»;&#13;
Российская медицинская академия непрерывного профессионального образования<country>Россия</country></aff><aff xml:lang="en">Central Research Institute of Tuberculosis;&#13;
Moscow Medical University "Reaviz";&#13;
Russian Medical Academy of Continuous Professional Education<country>Russian Federation</country></aff></aff-alternatives><pub-date pub-type="collection"><year>2025</year></pub-date><pub-date pub-type="epub"><day>01</day><month>08</month><year>2025</year></pub-date><volume>15</volume><issue>3</issue><fpage>118</fpage><lpage>128</lpage><permissions><copyright-statement>Copyright &amp;#x00A9; Медведев А.В., Аличубанова Г.Э., Демьяненко Н.Г., Касимцева С.А., Ковалевская М.Н., Тарасов Р.В., 2025</copyright-statement><copyright-year>2025</copyright-year><copyright-holder xml:lang="ru">Медведев А.В., Аличубанова Г.Э., Демьяненко Н.Г., Касимцева С.А., Ковалевская М.Н., Тарасов Р.В.</copyright-holder><copyright-holder xml:lang="en">Medvedev A.V., Alichubanova G.E., Dem'yanenko N.G., Kasimtseva S.A., Kovalevskaya M.N., Tarasov R.V.</copyright-holder><license license-type="creative-commons-attribution" xlink:href="https://creativecommons.org/licenses/by/4.0/" xlink:type="simple"><license-p>This work is licensed under a Creative Commons Attribution 4.0 License.</license-p></license></permissions><self-uri xlink:href="https://vestnik.reaviz.ru/jour/article/view/1275">https://vestnik.reaviz.ru/jour/article/view/1275</self-uri><abstract><p>Цель: изучить влияние эналаприла и валсартана + сакубитрила на уменьшение симптомов хронической сердечной недостаточности, на изменение функциональных и рентгенологических показателей у пациентов с гиперчувствительным пневмонитом, сочетанным с ишемической болезнью сердца. Объект и методы. Обследовано 183 пациента с гиперчувствительным пневмонитом: 88 пациентов с ишемической болезнью сердца и 95 пациентов без неё. Хроническая сердечная недостаточность диагностирована у 39 (44,3%) пациентов с ишемической болезнью сердца и у 13 (13,68%) пациентов с «изолированным» гиперчувствительным пневмонитом. В каждой группе проведены общеклинические, инструментальные, функциональные исследования. При оценке эффективности лечения хронической сердечной недостаточности пациенты разделены на две группы: 20 пациентам основной группы назначен эналаприл; 21 пациенту группы сравнения назначены валсартан + сакубитрил.Результаты. 24-недельная терапия позволила уменьшить проявления диастолической дисфункции: снижение индексированного конечно-систолического объёма левого предсердия на 5,13% в основной и на 11,2% в группе сравнения; конечно-диастолического объёма левого желудочка на 4,13% и 11,4% соответственно; уменьшение признаков гипертрофии левого желудочка – сокращение толщины его задней стенки на 3,2% в основной и 7,5% группе сравнения. Улучшение показателей эхокардиографии сопровождалось уменьшением интерстициальных изменений на компьтерной томографии, улучшением проходимости мелких и средних бронхов и показателей диффузионной способности лёгких, снижением выраженности клинических проявлений хронической сердечной недостаточности, что обосновывает применение сартанов в комплексной терапии хронической сердечной недостаточности у пациентов с гиперчувствительным пневмонитом, сочетанным с ишемической болезнью сердца.</p></abstract><trans-abstract xml:lang="en"><p>Objective: to study the effect of enalapril and valsartan + sacubitril on the reduction of CHF symptoms, on the change in functional and radiological parameters in patients with hypersensitivity pneumonitis (HP) combined with coronary heart disease. Materials and methods. 183 patients with hypersensitivity pneumonitis were examined: 88 patients with coronary artery disease and 95 patients without it. CHF was diagnosed in 39 (44.3%)% of CHD patients and in 13 (13.68%) "isolated" SHG. General clinical, instrumental and functional study methods were performed in each group. When assessing the effectiveness of CHF treatment, patients are divided into two groups: еnalapril was prescribed to 20 patients in the main group: 21 patients in the comparison group received valsartan + sacubitril. Results. 24-week therapy allowed to reduce the manifestations of diastolic dysfunction: a decrease in the indexed end-systolic volume of the left atrium by 5.13% in the main and 11.2% in the group, comparisons;, end-diastolic volume of the left ventricle by 4.13 and 11.4%, respectively; reduction of signs of left ventricular hypertrophy- reduction of its posterior wall thickness by 3.2% and 7.5%. The improvement in ECHOCG parameters was accompanied by a decrease in interstitial changes in CT, an improvement in the patency of small and medium bronchi and indicators of lung diffusion, a decrease in the severity of clinical manifestations of CHF, which justifies the use of sartans in the complex therapy of CHF in patients with hypersensitivity pneumonitis combined with coronary artery disease.</p></trans-abstract><kwd-group xml:lang="ru"><kwd>гиперчувствительный пневмонит [C08.381.677]</kwd><kwd>ишемическая болезнь сердца [C14.280.647.250]</kwd><kwd>хроническая сердечная недостаточность [C14.280.434]</kwd><kwd>эналаприл [D02.033.755.624.200.280]</kwd><kwd>валсартан [D02.033.755.624.200.875]</kwd><kwd>сакубитрил [D02.065.589.099.750]</kwd><kwd>диастолическая дисфункция [C14.280.484.150.550.925]</kwd><kwd>эхокардиография [E01.370.350.350.540]</kwd><kwd>антигипертензивная терапия [D27.505.696.663.050]</kwd><kwd>клиническое исследование [E05.318.372.500.750.249]</kwd></kwd-group><kwd-group xml:lang="en"><kwd>hypersensitivity pneumonitis / Pneumonia [C08.381.677]</kwd><kwd>coronary heart disease / Coronary Artery Disease [C14.280.647.250]</kwd><kwd>chronic heart failure / Heart Failure [C14.280.434]</kwd><kwd>enalapril [D02.033.755.624.200.280]</kwd><kwd>valsartan [D02.033.755.624.200.875]</kwd><kwd>sacubitril [D02.065.589.099.750]</kwd><kwd>diastolic dysfunction / Ventricular Dysfunction</kwd><kwd>Left [C14.280.484.150.550.925]</kwd><kwd>echocardiography [E01.370.350.350.540]</kwd><kwd>antihypertensive therapy / Antihypertensive Agents [D27.505.696.663.050]</kwd><kwd>clinical study / Clinical Trial [E05.318.372.500.750.249]</kwd></kwd-group></article-meta></front><back><ref-list><title>References</title><ref id="cit1"><label>1</label><citation-alternatives><mixed-citation xml:lang="ru">Raghu G., Remy-Jardin M., Ryerson Ch. J. et al. Diagnosis of hypersensitivity pneumonitis in adults. An Official ATS/JRS/ALAT Clinical Practice Guideline. Am. J. Respir. Crit. Care Med. 2020;202(3):e36–e69.</mixed-citation><mixed-citation xml:lang="en">Raghu G., Remy-Jardin M., Ryerson Ch. J. et al. Diagnosis of hypersensitivity pneumonitis in adults. An Official ATS/JRS/ALAT Clinical Practice Guideline. Am. J. Respir. Crit. Care Med. 2020;202(3):e36–e69.</mixed-citation></citation-alternatives></ref><ref id="cit2"><label>2</label><citation-alternatives><mixed-citation xml:lang="ru">Rittig A.H., Hilberg O., Ibsen R., Løkke A. Incidence, comorbidity and survival rate of hypersensitivity pneumonitis: a national populationbased study. ERJ Open. Res. 2019;5(4):00259–2018. https://doi.org/10.1183/23120541.00259-2018</mixed-citation><mixed-citation xml:lang="en">Rittig A.H., Hilberg O., Ibsen R., Løkke A. Incidence, comorbidity and survival rate of hypersensitivity pneumonitis: a national populationbased study. ERJ Open. Res. 2019;5(4):00259–2018. https://doi.org/10.1183/23120541.00259-2018</mixed-citation></citation-alternatives></ref><ref id="cit3"><label>3</label><citation-alternatives><mixed-citation xml:lang="ru">Julia Wälscher , Benjamin Gross, Julie Morisset , et al. Comorbidities and survival in patients with chronic hypersensitivity pneumonitis. Respir Res. 2020 Jan 9;21(1) 1283-1288. https://doi.org/10.1186/s12931-020-1283-1288</mixed-citation><mixed-citation xml:lang="en">Julia Wälscher , Benjamin Gross, Julie Morisset , et al. Comorbidities and survival in patients with chronic hypersensitivity pneumonitis. Respir Res. 2020 Jan 9;21(1) 1283-1288. https://doi.org/10.1186/s12931-020-1283-1288</mixed-citation></citation-alternatives></ref><ref id="cit4"><label>4</label><citation-alternatives><mixed-citation xml:lang="ru">Zhonghua Jie He, Wen-bing Xu, Min Peng et al. Clinical characteristic analysis of 96 cases of hypersensitivity pneumonitis. Chinese journal of tuberculosis and respiratory diseases. 2013 Feb; 36(2):83-87.</mixed-citation><mixed-citation xml:lang="en">Zhonghua Jie He, Wen-bing Xu, Min Peng et al. Clinical characteristic analysis of 96 cases of hypersensitivity pneumonitis. Chinese journal of tuberculosis and respiratory diseases. 2013 Feb; 36(2):83-87.</mixed-citation></citation-alternatives></ref><ref id="cit5"><label>5</label><citation-alternatives><mixed-citation xml:lang="ru">Avdeev SN, Aisanov ZR, Wiesel A.A. Hypersensitive pneumonitis. Adult clinical guidelines. Russian Respiratory Society, 2022, 56 p.</mixed-citation><mixed-citation xml:lang="en">Avdeev SN, Aisanov ZR, Wiesel A.A. Hypersensitive pneumonitis. Adult clinical guidelines. Russian Respiratory Society, 2022, 56 p.</mixed-citation></citation-alternatives></ref><ref id="cit6"><label>6</label><citation-alternatives><mixed-citation xml:lang="ru">Barnett J, Molyneaux PL, Rawal B et al. Variable utility of mosaic attenuation to distinguish fibrotic hypersensitivity pneumonitis from idiopathic pulmonary fibrosis. Eur. Respir J. 2019;54(1):1900531. https://doi.org/10.1183/13993003.00531-2019</mixed-citation><mixed-citation xml:lang="en">Barnett J, Molyneaux PL, Rawal B et al. Variable utility of mosaic attenuation to distinguish fibrotic hypersensitivity pneumonitis from idiopathic pulmonary fibrosis. Eur. Respir J. 2019;54(1):1900531. https://doi.org/10.1183/13993003.00531-2019</mixed-citation></citation-alternatives></ref><ref id="cit7"><label>7</label><citation-alternatives><mixed-citation xml:lang="ru">Авдеев С.Н. Гиперчувствительный пневмонит. Пульмонология. 2021;31(1):88-99. https://doi.org/10.18093/0869-0189-2021-31-1-88-99</mixed-citation><mixed-citation xml:lang="en">Avdeev S.N. Hypersensitivity pneumonitis. Pulmonology. 2021;31(1):88-99. (In Russ.). https://doi.org/10.18093/0869-0189-2021-31-1-88-99</mixed-citation></citation-alternatives></ref><ref id="cit8"><label>8</label><citation-alternatives><mixed-citation xml:lang="ru">Fiddler C.A., Simler N., Thillai M., Parfrey H. Use of mycophenolate mofetil and azathioprine for the treatment of chronic hypersensitivity pneumonitis – A single‐centre experience. Clin. Respir. J. 2019;13(12):791–794. https://doi.org/10.1111/crj.13086</mixed-citation><mixed-citation xml:lang="en">Fiddler C.A., Simler N., Thillai M., Parfrey H. Use of mycophenolate mofetil and azathioprine for the treatment of chronic hypersensitivity pneumonitis – A single‐centre experience. Clin. Respir. J. 2019;13(12):791–794. https://doi.org/10. 1111/crj.13086</mixed-citation></citation-alternatives></ref><ref id="cit9"><label>9</label><citation-alternatives><mixed-citation xml:lang="ru">Драпкина О. М, Лопатин Ю. М, Ситникова М. Ю. и др. Хроническая сердечная недостаточность. Клинические рекомендации. Кардиология. 2018;58(S6). https://doi.org/10.18087/cardio.2475</mixed-citation><mixed-citation xml:lang="en">Drapkina O. M., Lopatin Yu. M., Sitnikova M. Yu. and others. Chronic heart failure. Clinical guidelines, 166 pages. Cardiology. 2018;58(S6). (In Russ.). https://doi.org/10.18087/cardio.2475</mixed-citation></citation-alternatives></ref><ref id="cit10"><label>10</label><citation-alternatives><mixed-citation xml:lang="ru">Авдеев С.Н, Айсанов З.Р, Визель А.А. с соат. Гиперчувствительный пневмонит. Клинические рекомендации. Российское респираторное общество. 2024:57.</mixed-citation><mixed-citation xml:lang="en">Avdeev S.N., Aisanov Z.R., Wiesel A.A. et al. Hypersensitivity pneumonitis. Clinical recommendations. Russian Respiratory Society. 2024:57. (In Russ.).</mixed-citation></citation-alternatives></ref><ref id="cit11"><label>11</label><citation-alternatives><mixed-citation xml:lang="ru">Барбараш О. Л., Карпов Ю.А., Панов А.В с соавт. Стабильная ишемическая болезнь сердца. Клинические рекомендации 2024. Российский кардиологический журнал. 2024;29(9):6110. https://doi.org/10.15829/1560-4071-2024-6110</mixed-citation><mixed-citation xml:lang="en">Barbarash O. L., Karpov Yu.A., Panov A.V. et al. Stable coronary heart disease. Clinical guidelines 2024. Russian Journal of Cardiology. 2024;29(9):6110. (In Russ.). https://doi.org/10.15829/1560-4071-2024-6110</mixed-citation></citation-alternatives></ref><ref id="cit12"><label>12</label><citation-alternatives><mixed-citation xml:lang="ru">Кобалава Ж. Д., Конради А. О., Недогода С. В с соавт. Артериальная гипертензия у взрослых. Клинические рекомендации 2024. Российский кардиологический журнал. 2024;29(9):6117. https://doi.org/10.15829/ 1560-4071-2024-6117</mixed-citation><mixed-citation xml:lang="en">Kobalava J. D., Konradi A. O., Nedogoda S. In c et al. Arterial hypertension in adults. Clinical guidelines 2024. Russian Journal of Cardiology. 2024;29(9):6117. (In Russ.). https://doi.org/10.15829/ 1560-4071-2024-6117</mixed-citation></citation-alternatives></ref><ref id="cit13"><label>13</label><citation-alternatives><mixed-citation xml:lang="ru">Аракелян М. Г., Бокерия Л. А., Васильева Е. Ю. с соавт. Фибрилляция и трепетание предсердий. Клинические рекомендации 2020. Российский кардиологический журнал. 2021;26(7):4594. https://doi.org/10.15829/1560-4071-2021-4594</mixed-citation><mixed-citation xml:lang="en">Arakelyan M. G., Bokeria L. A., Vasilyeva E. Yu. et al. Atrial fibrillation and flutter. Clinical guidelines 2020. Russian Journal of Cardiology. 2021;26(7):4594. (In Russ.). https://doi.org/10.15829/1560-4071-2021-4594</mixed-citation></citation-alternatives></ref><ref id="cit14"><label>14</label><citation-alternatives><mixed-citation xml:lang="ru">Галявич А. С, Терещенко С. Н, Ускач Т.М. с соавт. Хроническая сердечная недостаточность. Клинические рекомендации 2024 г. Российский кардиологический журнал. 2024; 29(11):6162. https://doi.org/10.15829/1560-4071-2024-6162</mixed-citation><mixed-citation xml:lang="en">Galyavich A. S., Tereshchenko S. N., Uskach T.M. et al. Chronic heart failure. Clinical Guidelines 2024. Russian Journal of Cardiology. 2024;29(11):6162. (In Russ.). https://doi.org/10.15829/1560-4071-2024-6162</mixed-citation></citation-alternatives></ref><ref id="cit15"><label>15</label><citation-alternatives><mixed-citation xml:lang="ru">Nerys Williams. The MRC breathlessness scale. Occup. Med (Lond.). 2017, Aug 1;67(6):496-497. https://doi.org/10.1093/occmed/kqx086</mixed-citation><mixed-citation xml:lang="en">Nerys Williams. The MRC breathlessness scale. Occup. Med (Lond.). 2017, Aug 1;67(6):496-497. https://doi.org/10.1093/occmed/kqx086</mixed-citation></citation-alternatives></ref><ref id="cit16"><label>16</label><citation-alternatives><mixed-citation xml:lang="ru">Jane E Reynolds, Marie E Jetté, Miranda L. Wright, Krishna M. Sundar, et al. Normative Values for the Leicester Cough Questionnaire in Healthy Individuals. Ann. Otol. Rhinol. Laryngol. 2022 Jul. 14; 34894221112517. https://doi.org/10.1177/00034894221112517</mixed-citation><mixed-citation xml:lang="en">Jane E Reynolds, Marie E Jetté, Miranda L. Wright, Krishna M. Sundar, et al. Normative Values for the Leicester Cough Questionnaire in Healthy Individuals. Ann. Otol. Rhinol. Laryngol. 2022 Jul. 14; 34894221112517. https://doi.org/10.1177/00034894221112517</mixed-citation></citation-alternatives></ref><ref id="cit17"><label>17</label><citation-alternatives><mixed-citation xml:lang="ru">Мареев В.Ю., Даниелян М.О., Беленков Ю.Н. От имени рабочей группы исследования ЭПОХА-О-ХСН. Сравнительная характеристика больных с ХСН в зависимости от величины фракции выброса левого желудочка по результатам Российского многоцентрового исследования ЭПОХА-О-ХСН. Сердечная недостаточность. 2006;7(4):164-171.</mixed-citation><mixed-citation xml:lang="en">Mareev V.Yu., Danielyan M.O., Belenkov Yu.N. On behalf of the EPOCH-O-CHF research working group. Comparative characteristics of patients with CHF depending on the size of the left ventricular ejection fraction according to the results of the Russian multicenter study EPOCH-O-CHF. Heart failure. 2006;7(4):164-171. (In Russ.).</mixed-citation></citation-alternatives></ref><ref id="cit18"><label>18</label><citation-alternatives><mixed-citation xml:lang="ru">Warrick JH, Bhalla M, Schabel SI, Silver RM. High resolution computed tomography in early scleroderma lung disease. J Rheumatol. 1991;18(10):1520-8.</mixed-citation><mixed-citation xml:lang="en">Warrick JH, Bhalla M, Schabel SI, Silver RM. High resolution computed tomography in early scleroderma lung disease. J Rheumatol. 1991;18(10):1520-8.</mixed-citation></citation-alternatives></ref><ref id="cit19"><label>19</label><citation-alternatives><mixed-citation xml:lang="ru">Yancy CW, Jessup M, Bozkurt B, Butler J, Casey DE, Colvin MM et al. 2017 ACC/AHA/HFSA Focused Update of the 2016 ACCF/AHA Guideline for the Management of Heart Failure: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines and the Heart Failure Society of America Circulation. 2017 136(6):e137–61. https://doi.org/10.1161/CIR.0000000000000509</mixed-citation><mixed-citation xml:lang="en">Yancy CW, Jessup M, Bozkurt B, Butler J, Casey DE, Colvin MM et al. 2017 ACC/AHA/HFSA Focused Update of the 2016 ACCF/AHA Guideline for the Management of Heart Failure: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines and the Heart Failure Society of America Circulation. 2017 136(6):e137–61. https://doi.org/10.1161/CIR. 0000000000000509</mixed-citation></citation-alternatives></ref><ref id="cit20"><label>20</label><citation-alternatives><mixed-citation xml:lang="ru">Thomas L., Marwick T.H., Popescu B.A., Donal E. et al. Left atrial structure and function, and left ventricular diastolic dysfunction: JACC stateof-the-art review. J. Am. Coll. Cardiol. 2019;73(15):1961–77. https://doi.org/10.1016/j.jacc.2019.01.059</mixed-citation><mixed-citation xml:lang="en">Thomas L., Marwick T.H., Popescu B.A., Donal E. et al. Left atrial structure and function, and left ventricular diastolic dysfunction: JACC stateof-the-art review. J. Am. Coll. Cardiol. 2019;73(15):1961–77. https://doi.org/10.1016/j.jacc.2019.01.059</mixed-citation></citation-alternatives></ref><ref id="cit21"><label>21</label><citation-alternatives><mixed-citation xml:lang="ru">Velazquez EJ, Morrow DA, DeVore AD, et al.; PIONEER-HF Investigators. AngiotensinNeprilysin Inhibition in Acute Decompensated Heart Failure. N Engl J Med. 2019;380(6):539-48. https://doi.org/10.1056/NEJMoa1812851. Erratum in: N. Engl. J. Med. 2019;380(11):1090. https://doi.org/10.1056/NEJMx190009</mixed-citation><mixed-citation xml:lang="en">Velazquez EJ, Morrow DA, DeVore AD, et al.; PIONEER-HF Investigators. AngiotensinNeprilysin Inhibition in Acute Decompensated Heart Failure. N Engl J Med. 2019;380(6):539-48. https://doi.org/10.1056/NEJMoa1812851. Erratum in: N. Engl. J. Med. 2019;380(11):1090. https://doi.org/10.1056/NEJMx190009</mixed-citation></citation-alternatives></ref><ref id="cit22"><label>22</label><citation-alternatives><mixed-citation xml:lang="ru">Yancy CW, Jessup M, Bozkurt B, Butler J, Casey DE, Colvin MM et al. 2017 ACC/AHA/HFSA Focused Update of the 2016 ACCF/AHA Guideline for the Management of Heart Failure: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines and the Heart Failure Society of America Circulation. 2017;136(6):e137–61. https://doi.org/10.1161/CIR.0000000000000509</mixed-citation><mixed-citation xml:lang="en">Yancy CW, Jessup M, Bozkurt B, Butler J, Casey DE, Colvin MM et al. 2017 ACC/AHA/HFSA Focused Update of the 2016 ACCF/AHA Guideline for the Management of Heart Failure: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines and the Heart Failure Society of America Circulation. 2017;136(6):e137–61. https://doi.org/10.1161/CIR.0000000000000509</mixed-citation></citation-alternatives></ref></ref-list><fn-group><fn fn-type="conflict"><p>The authors declare that there are no conflicts of interest present.</p></fn></fn-group></back></article>
